{"id":"NCT00916006","sponsor":"Peplin","briefTitle":"A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","officialTitle":"A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.015% In Patients With Actinic Keratoses ON the Head (Face or Scalp) (REGION-IIa)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2009-09","completion":"2009-09","firstPosted":"2009-06-08","resultsPosted":"2012-03-21","lastUpdate":"2015-04-02"},"enrollment":269,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratosis"],"interventions":[{"type":"DRUG","name":"PEP005 Gel","otherNames":["PEP005"]},{"type":"DRUG","name":"Vehicle gel","otherNames":["Placebo"]}],"arms":[{"label":"PEP005 gel","type":"EXPERIMENTAL"},{"label":"Vehicle gel","type":"PLACEBO_COMPARATOR"}],"summary":"This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.","primaryOutcome":{"measure":"Patients With Complete Clearance of Actinic Keratosis (AK) Lesions.","timeFrame":"57 days","effectByArm":[{"arm":"PEP005 (Ingenol Mebutate) Gel","deltaMin":50,"sd":null},{"arm":"Vehicle Gel","deltaMin":3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":21,"countries":["United States","Australia"]},"refs":{"pmids":["22417254"],"seeAlso":["http://www.fda.gov","http://www.tga.gov.au"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":132},"commonTop":["APPLICATION SITE PAIN","APPLICATION SITE PRURITUS"]}}